Interview part two: Chang Yi Wang, Chairperson & CEO, UBI Asia, and…
In the second part of this two-part interview, the Chairperson of UBI and UBI Asia offers her thoughts on the challenges and opportunities of the Chinese market, and explains her…
UBI is a privately held multinational biopharmaceutical company dedicated to the discovery, development and commercialization of immunotherapeutics and vaccines for chronic and infectious diseases.
The company’s product pipeline is filled with a new line of synthetic peptide-based biologicals for the treatment and prevention of Alzheimer’s Disease, AIDS, and Allergy, along with a portfolio of animal health diseases. These products are based on UBI’s proprietary designer peptides, vaccine formulation systems, and methods to manufacture therapeutic monoclonal antibodies. The company’s platform technologies are also being used to develop a line of biosimilar versions of widely used protein and antibody drugs whose patents are about to expire.
UBI’s proprietary designer peptide technology has been used to produce a line of blood screening diagnostics and the first successfully commercialized synthetic peptide vaccine. Additional revenue streams are generated from pharmaceutical contract manufacturing by the company’s subsidiary UBI-Asia and various sponsorships in product development.
Rm. E, 52F., No.7-5,
Sec. 5, Xinyi Rd.,
Xinyi Dist.,
Taipei City
11049,
Taiwan (R.O.C.)
Tel:886-2-8101-0101
Fax:886-2-8101-0100
In the second part of this two-part interview, the Chairperson of UBI and UBI Asia offers her thoughts on the challenges and opportunities of the Chinese market, and explains her…
In the first of this two-part interview, the chairperson of UBI and UBI Asia explains the work that her company has done to improve the landscape for Taiwanese pharma and…
The Taiwanese pharmaceutical industry has reached a crucial tipping point: After many years of building up an impressive resource base, from world-class research institutes, universities, and scientists to pharmaceutical…
Could you start with an overview of the hospital’s capabilities and areas of focus in 2010? NTUH is a 2500 bed medical center and JCI accredited. We are a Centre…
How would you describe Morris Enterprise to our readers? Morris Enterprise is a distributor of pharmaceuticals, nutraceuticals and cosmoceuticals. The company has a pharmaceutical division in marketing, a division in…
In 2002, when you established Golden Biotech, what was your vision for the company? There has always been a focus on creating drugs to cure cancer: there are many good…
Traditionally and historically, Lilly is very strong in the Asian region. The company has placed a great deal of emphasis on the region for many years. How does Taiwan fit…
Paul Krugman, who won the 2006 Nobel Prize in economics, said that the Taiwanese health care system is the best in the world. Despite this, you are now drafting a…
Pharma Power Biotec was founded in 2002. What was the vision behind the creation of the company, and what did you want to achieve with the company when it was…
In January 2010, the Taiwan FDA was newly created from four existing agencies. What was the vision behind the creation of this new organisation? What did the government want to…
Minister Wu, please tell our readers a little about your background, and how you came to be in charge of the Overseas Compatriot Affairs Commission (OCAC). I graduated from National…
When you created PharmaEssentia, what was the rationale behind coming back to Taiwan? The foundation for the company was laid in 1997. A group of Taiwanese government officials came to…
Yung Shin has a very long and well-regarded history here in Taiwan. Perhaps we could start by you telling our readers about the recent history of the company and its…
Where is NatureWise most focused today as a company? NatureWise is mainly focused on histone deacetylase (HDAC) inhibitors, especially in the new area of anti-cancer target therapy. These HDAC inhibitor…
See our Cookie Privacy Policy Here
